SAN DIEGO, CA--(Marketwired - Aug 26, 2014) - Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced the appointment of Richard C. Williams, Robert B. Rothermel and William C. Denby to its Board of Directors. Mr. Williams was also appointed as Chairman of the Board.
Dr. Dennis J. Carlo, President and CEO of Adamis, stated, "We are very excited to bring on these new members with such strong credentials to Adamis' Board. They bring tremendous operational, M & A, sales and marketing, financial, accounting, and healthcare leadership to the table. Collectively, they provide us with years of experience and expertise that will enable us to move into sales, marketing and commercialization of our specialty pharmaceuticals products. Their proven track record, knowledge and relationships in the specialty pharmaceuticals area will be an asset to the company as we continue to add new products to our pipeline."
The new board additions include:
Richard C. Williams: Since 1989, Mr. Williams has served as the founder and President of Conner-Thoele Limited, a consulting and financial advisory firm specializing in the healthcare industry and pharmaceutical segment. He has completed in excess of fifty divestments, acquisitions, financings and cross-border transactions, which have exceeded $8.0 billion. Prior to founding Conner-Thoele Limited in 1989, Mr. Williams served in a number of progressively responsible operational and financial management positions with multinational firms. These firms included American Hospital Supply Corporation, UNC Resources, Abbott Laboratories, Field Enterprises and Erbamont NV. Mr. Williams once served as a director and Vice Chairman of Strategic Planning for King Pharmaceuticals. Prior to King, he served as Chairman and a director of Medco Research before Medco was acquired by King Pharmaceuticals. Mr. Williams has also been on several other public and private Board of Directors, several as Chairman and a Director. These include Ista Pharmaceuticals, Vysis Pharmaceuticals, Immunemedics, EP Medical and Cellegy Pharmaceuticals. He was a member of the Listed Company Advisory Committee of New York Stock Exchange. Mr. Williams received a Bachelor of Arts degree in Economics from DePauw University and a Masters of Business Administration from the Wharton School of Finance.
Robert B. Rothermel: Mr. Rothermel is a partner with a private investment and management firm, CroBern Management Partnership, which works exclusively within the health care industry. Currently, he serves as a board member and chairman of the audit committee of Medcor and has also served as a board member of Cerescan, a private brain imaging company. Prior to CroBern, Mr. Rothermel spent 37 years with Deloitte & Touche, and served as a Partner and Global Managing Director of the Enterprise Risk Services practice. He also served as a member of Deloitte & Touche's Board of Directors, the firm's Global Assurance and Advisory Management Committee, the U.S. Management Committee and chaired the firm's Partner Compensation Committee. Mr. Rothermel has a Bachelor of Science degree in Business Administration from Bowling Green State University.
William C. Denby: From 2002-2014, Mr. Denby was Senior Vice President, Commercial Operations at Santarus, Inc. which was acquired by Salix in January of 2014. At Santarus, he directed all commercial functions including Sales, Marketing, Market Research, Customer Service, Managed Care, New Product Planning and other various functions. Prior to Santarus, he was Senior Vice President, Commercial Operations and Senior Vice President, Sales and Marketing at Agouron Pharmaceuticals, Inc. Mr. Denby played key leadership roles in the sale of Agouron to Warner Lambert for $2.2 billion and Santarus to Salix for $2.6 billion. Earlier in his career, he spent twenty years in various leadership management roles at Marion Merrell Dow, Inc. Mr. Denby has a Bachelor of Arts degree in English and Business from State University of New York at Fredonia and a Masters of Business Administration from Rockhurst College.
These three new independent board members have replaced Tina S. Nova, Ph.D., Craig A. Johnson and Kenneth M. Cohen, who resigned from the Board. Additional information concerning their resignation is contained in a report on Form 8-K that the company will file with the Securities and Exchange Commission.
Dr. Carlo added, "The Company would like to thank Tina S. Nova, Craig A. Johnson and Kenneth M. Cohen for their contributions in helping grow the company and wish them the very best in their future endeavors."
About Adamis Pharmaceuticals Corporation
Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology. The company's current specialty pharmaceutical product candidates include the Epinephrine Injection PFS syringe product for use in the emergency treatment of anaphylaxis, APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease, and APC-3000, an HFA inhaled nasal steroid product for the treatment of allergic rhinitis. The company's vaccine product candidates and cancer drug product candidates under research and development include TeloB-VAX, a cell-based therapeutic cancer vaccine and three drugs, APC-100, APC-200, and APC-300, for the treatment of prostate cancer.
Director, Investor Relations &
Adamis Pharmaceuticals Corporation